Hartford Investment Management Co. Reduces Holdings in DaVita Inc. (NYSE:DVA)

Hartford Investment Management Co. decreased its stake in shares of DaVita Inc. (NYSE:DVA) by 11.7% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,934 shares of the company’s stock after selling 390 shares during the period. Hartford Investment Management Co.’s holdings in DaVita were worth $481,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Blue Trust Inc. boosted its position in DaVita by 58.6% during the 2nd quarter. Blue Trust Inc. now owns 211 shares of the company’s stock valued at $29,000 after acquiring an additional 78 shares in the last quarter. Family Firm Inc. purchased a new position in shares of DaVita in the 2nd quarter valued at approximately $43,000. Versant Capital Management Inc boosted its position in shares of DaVita by 90.6% during the second quarter. Versant Capital Management Inc now owns 326 shares of the company’s stock valued at $45,000 after purchasing an additional 155 shares in the last quarter. Friedenthal Financial purchased a new stake in DaVita in the second quarter worth $48,000. Finally, Point72 Hong Kong Ltd bought a new position in DaVita in the second quarter worth $68,000. Hedge funds and other institutional investors own 90.12% of the company’s stock.

Analyst Upgrades and Downgrades

DVA has been the topic of a number of research reports. TD Cowen boosted their target price on shares of DaVita from $139.00 to $150.00 and gave the company a “hold” rating in a report on Wednesday, July 24th. Bank of America boosted their price objective on shares of DaVita from $139.00 to $145.00 and gave the stock an “underperform” rating in a research note on Wednesday, August 7th. Truist Financial upped their price objective on shares of DaVita from $165.00 to $175.00 and gave the stock a “hold” rating in a report on Monday, October 7th. Finally, UBS Group lifted their target price on shares of DaVita from $169.00 to $175.00 and gave the company a “buy” rating in a report on Thursday, August 8th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, DaVita presently has an average rating of “Hold” and an average target price of $159.00.

DaVita Stock Down 2.7 %

NYSE:DVA opened at $156.99 on Friday. The company has a debt-to-equity ratio of 9.94, a quick ratio of 1.12 and a current ratio of 1.16. The firm has a market cap of $13.77 billion, a P/E ratio of 17.84, a P/E/G ratio of 0.93 and a beta of 0.87. DaVita Inc. has a fifty-two week low of $75.47 and a fifty-two week high of $168.50. The firm has a 50-day simple moving average of $158.09 and a two-hundred day simple moving average of $145.58.

DaVita (NYSE:DVA) last announced its quarterly earnings results on Tuesday, August 6th. The company reported $2.59 earnings per share for the quarter, beating the consensus estimate of $2.47 by $0.12. The company had revenue of $3.19 billion during the quarter, compared to the consensus estimate of $3.15 billion. DaVita had a net margin of 6.86% and a return on equity of 77.00%. The firm’s quarterly revenue was up 6.2% compared to the same quarter last year. During the same quarter last year, the firm earned $2.08 earnings per share. Analysts predict that DaVita Inc. will post 9.99 earnings per share for the current fiscal year.

Insider Transactions at DaVita

In related news, CEO Javier Rodriguez sold 50,000 shares of the stock in a transaction on Monday, September 16th. The stock was sold at an average price of $165.05, for a total transaction of $8,252,500.00. Following the sale, the chief executive officer now directly owns 837,835 shares of the company’s stock, valued at $138,284,666.75. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In other DaVita news, CEO Javier Rodriguez sold 50,000 shares of the company’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $165.05, for a total transaction of $8,252,500.00. Following the transaction, the chief executive officer now owns 837,835 shares in the company, valued at approximately $138,284,666.75. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Kathleen Alyce Waters sold 7,857 shares of DaVita stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $146.21, for a total transaction of $1,148,771.97. Following the completion of the sale, the insider now owns 83,011 shares of the company’s stock, valued at $12,137,038.31. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 173,482 shares of company stock worth $27,387,069 over the last quarter. 2.00% of the stock is currently owned by insiders.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.